We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Shockwave Coronary Lithoplasty® Study (Disrupt CAD II)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03328949
Recruitment Status : Completed
First Posted : November 1, 2017
Results First Posted : November 8, 2019
Last Update Posted : November 19, 2019
Information provided by (Responsible Party):
Shockwave Medical, Inc.

Brief Summary:
The objective of this post market study is to examine the safety and performance of the Shockwave Coronary Intravascular Lithotripsy System for the treatment of narrowed coronary arteries before the doctor places a stent.

Condition or disease Intervention/treatment Phase
Coronary Artery Disease Device: IVL Coronary Lithotripsy System Not Applicable

Detailed Description:

The study will be conducted at 15 sites in Europe and up to 120 participants will be followed for 30 days post procedure.

Patients ≥18 years of age scheduled for stent procedure with evidence of significant calcified stenosis of left main, or left anterior descending, right coronary artery or left circumflex will be eligible to enroll in the study. The primary endpoint of the study will evaluate major adverse cardiac events post procedure including 1) cardiac related death, 2) heart attack, and 3) intervention to treat the coronary artery that was previously treated at the procedure visit.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 120 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Intravascular Coronary Lithotripsy System
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective Multi-Center, Single Arm Post-Market Study (PMS) of the Shockwave Medical, Inc. Coronary Lithoplasty® System in Coronary Arteries
Actual Study Start Date : May 18, 2018
Actual Primary Completion Date : March 26, 2019
Actual Study Completion Date : April 25, 2019

Arm Intervention/treatment
Experimental: IVL Coronary Lithotripsy System
All enrolled patients will receive treatment from the IVL coronary lithotripsy system prior to coronary stent placement.
Device: IVL Coronary Lithotripsy System
The coronary intravascular lithotripsy catheter is similar to other balloon devices that are routinely used during angioplasty procedures; however, it has electrodes inside the balloon which are designed to deliver energy to crack the calcified blockage using lithotripsy (acoustic energy).

Primary Outcome Measures :
  1. Number of Participants With In-hospital Major Adverse Cardiac Events (MACE) [ Time Frame: Post-procedure through hospital discharge ]

    The primary endpoint is the frequency of in-hospital major adverse cardiac events (MACE). MACE is defined as the following:

    • Cardiac death
    • Myocardial Infarction - defined as a CK-MB level > 3 times the upper limit of lab normal (ULN) value with or without new pathologic Q wave
    • TVR - defined as revascularization at the target vessel (inclusive of the target lesion) after the completion of the index procedure

Secondary Outcome Measures :
  1. Number of Participants With Clinical Success [ Time Frame: During procedure through hospital discharge ]
    Performance will be assessed by the ability of the Lithotripsy System to produce acceptable residual stenosis (<50%) after stenting with no evidence of in-hospital MACE. Each patient that achieves both of these requirements will be considered a "clinical success", and the rate of clinical success among subjects will be evaluated.

  2. Number of Participants With Angiographic Success [ Time Frame: During procedure ]
    Angiographic success defined as success in facilitating stent delivery with <50% residual stenosis and without serious angiographic complications. Serious angiographic complications defined as severe dissection (Type D to F), perforation, abrupt closure, and persistent slow flow or persistent no reflow.

  3. Number of Participants Which Experienced Cardiac Death [ Time Frame: 30 days post-procedure ]
    Number of patients who experienced a cardiac death at 30 days post-procedure.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patient is ≥ 18 years of age
  2. Troponin must be less than or equal to the upper limit of lab normal value within 24 hours prior to the procedure OR if troponin is elevated, concomitant CK must be normal
  3. The target vessel must have a TIMI flow 3 at baseline
  4. Patients with significant (≥ 50% diameter stenosis) native coronary artery disease including stable or unstable angina and silent ischemia, suitable for PCI
  5. Ability to tolerate dual antiplatelet agent (i.e. aspirin, clopidogrel, prasugrel, or ticagrelor) for 1 year and single antiplatelet therapy for life
  6. Single lesion stenosis of protected LMCA, or LAD, RCA or LCX artery ≥50% in a reference vessel of 2.5 mm - 4.0 mm diameter and ≤ 32 mm length
  7. Presence of calcification within the lesion on both sides of the vessel as assessed by angiography
  8. Planned treatment of single lesion in one vessel
  9. Ability to pass a 0.014" guide wire across the lesion
  10. Patient, or authorized representative, signs a written Informed Consent form to participate in the study, prior to any study-mandated procedures
  11. Patient is able and willing to comply with all assessments in the study

Exclusion Criteria:

  1. Concomitant use of Atherectomy, Specialty balloon, or investigational coronary devices
  2. Prior PCI procedure within the last 30 days of the index procedure
  3. Patient has planned cardiovascular interventions within 30 days post index procedure
  4. Second lesion with ≥50% stenosis in the same target vessel
  5. Left ventricular ejection fraction < 40%
  6. Patient refusing or not a candidate for emergency coronary artery bypass grafting (CABG) surgery
  7. Uncontrolled severe hypertension (systolic BP >180 mm Hg or diastolic BP >110 mm Hg)
  8. Severe renal failure with serum creatinine >2.5 mg/dL, unless on chronic dialysis
  9. Untreated pre-procedural hemoglobin <10 g/dL
  10. Coagulopathy manifested by platelet count <100,000 or International Normalized ratio (INR) >1.7 (INR is only required in patients who have taken warfarin within 2 weeks of enrollment)
  11. Patients in cardiogenic shock
  12. Acute myocardial infarction (MI) within the past one (1) month, and/or signs of active myocardial ischemia at the time of enrollment including elevated Troponin-I or T (with concomitant elevation of CK), ischemic ECG changes or chest pain
  13. History of a stroke or transient ischemic attack (TIA) within 3 months
  14. NYHA class III or IV heart failure
  15. Active peptic ulcer or upper gastrointestinal (GI) bleeding within 6 months
  16. Patients with a life expectancy of less than 1 year
  17. Target vessel < 2.4 mm in diameter
  18. Target lesion > 32 mm in length
  19. Chronic Total Occlusion (CTO)
  20. Previous stent procedure within 5 mm of target lesion
  21. Angiographic evidence of a target lesion severe dissection prior to Coronary Lithoplasty treatment
  22. Unprotected Left Main diameter stenosis ≥ 50%
  23. Visible thrombus (by angiography) at target lesion site
  24. Target lesion is located in a native vessel distal to anastomosis with a saphenous vein graft or LIMA/RIMA bypass
  25. Patient has active systemic infection
  26. Patient has connective tissue disease (e.g., Marfan's syndrome)
  27. Patient has a hypercoagulable disorder
  28. Uncontrolled insulin dependent diabetes
  29. Patient has allergy to imaging contrast media for which they cannot be pre-medicated
  30. Evidence of aneurysm in target vessel
  31. Patient is pregnant or nursing

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03328949

Layout table for location information
Aalst, Belgium
Aarhus Universitetshospital
Aarhus, Denmark
Institut Hospitalier Jacques Cartier
Massy, France
Clinique Pasteur
Toulouse, France
Universitaets-Herzzentrum Freiburg- Bad Krozingen
Bad Krozingen, Germany
Universitaetsklinikum Bonn
Bonn, Germany
UKGM Universitaetsklinikum Giessen
Gießen, Germany
AOU Careggi SOD Interventistica
Firenze, Italy
San Raffaelle Hospital
Milan, Italy
Thorax Center, Erasmus MC
Rotterdam, Netherlands
Isala Zeikenhuis- Hartecentrum
Zwolle, Netherlands
Hospital Universitario San Carlos
Madrid, Spain
Uppsala University Hospital
Uppsala, Sweden
United Kingdom
King's College Hospital
London, United Kingdom
Oxford University Hospitals, John Radcliffe Hospital
Oxford, United Kingdom
Sponsors and Collaborators
Shockwave Medical, Inc.
Layout table for investigator information
Principal Investigator: Jean Fajadet, MD Clinic Pasteur
Principal Investigator: Carlo DiMario, MD University of Florence
  Study Documents (Full-Text)

Documents provided by Shockwave Medical, Inc.:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Shockwave Medical, Inc.
ClinicalTrials.gov Identifier: NCT03328949    
Other Study ID Numbers: CP61774
First Posted: November 1, 2017    Key Record Dates
Results First Posted: November 8, 2019
Last Update Posted: November 19, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases